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Abstract 
Primary sarcomas of the liver are rare tumors
and their diagnosis is difficult to assess, particu-
larly  on  percutaneous  liver  biopsy.  Epithelioid
hemangioendothelioma (EHE) is an infrequent
indication  for  liver  transplantation,  and
angiosarcoma (AS) is a widely recognized con-
traindication because of its poor prognosis. We
report the case of a young woman who under-
went liver transplantation (LT) for an infiltrative
hepatic tumor with several features suggestive
of EHE, although the analysis of the native liver
revealed AS. Everolimus was used as the main
immunosuppressive drug. More than two years
after LT, her physical condition remained stable
despite a local recurrence at 10 months. In this
setting, the ranking of new immunosuppressive
agents belonging to the family of the prolifera-
tion signal inhibitors will need to be precise, but
their intrinsic properties suggest a potential use
in treatments after LT for atypical malignancies.
Introduction
Primary sarcomas of the liver are rare tumors
(approximately  1%  of  liver  cancers)  and  an
exceptional indication for liver transplantation
(LT).
1 The  two  main  histological  forms  are
epithelioid  hemangioendothelioma  (EHE)  and
angiosarcoma (AS).
2 Those tumors, which share
the same mesenchymal origin (endothelial cells
edging the sinusoid), have very different natural
history  and  prognosis,  and  require  different
treatments (Table 1). Although LT can be indicat-
ed in some cases of EHE because of a favorable
long term outcome,
1,3 it is absolutely not advised
for AS owing to a high risk of early local or gen-
eral recurrence after LT.4 We report the case of a
young woman who underwent LT for a infiltra-
tive hepatic tumor, of which some characteris-
tics and the clinical presentation were sugges-
tive of EHE. However, the histological analysis of
the explanted liver revealed AS. The preventive
use of an immunosuppressive drug with antipro-
liferative  properties  belonging  to  the  mam-
malian target of rapamycine (mTOR) inhibitors
led  to  the  usual  two  years’  survival  after  LT,
despite a local recurrence of AS.
Case Report 
A 41-year-old woman was admitted in April
2002  for  acute  hepatitis  of  unknown  etiology.
Previous  liver  function  tests,  performed  in
March 2002, were normal. The only remarkable
medical history was obesity with a body mass
index of 31.5. There was no history of excessive
alcohol consumption (30 g/wk), medication, or
toxic exposure. Biological testing excluded viral,
bacterial, and autoimmune hepatitis. The com-
puterized  tomography  (CT)  scan  revealed  a
homogeneous  hepatomegaly  and  excluded  a
thrombosis of the sus-hepatic veins. A liver biop-
sy showed a granulomatous infiltration of the
liver, with histiocytes but no centrolobular necro-
sis, as well as a steatosis (30% of the parenchy-
ma). The diagnosis of acute hepatitis related to
a vascularitis was made. Between 2002 and 2005
she  was  hospitalized  for  several  episodes  of
acute disease, associated fever, maculopapulous
eruption, elevation of liver enzymes (AST = 5 x
ULN, ALT = 11 x ULN), and cholestasis (alkaline
phosphatases = 20 x ULN, γGT = 10 x ULN).
Because of the lack of success of the previous
therapy, a systemic corticotherapy (dexametha-
sone = 250 mg IV) was begun in 2005, followed
by oral prednisone (1 mg/kg/day). In May 2005 a
low platelet count (99000/mm
3) was observed.
The patient underwent a second liver biopsy. A
vascular  disease  predominant  in  the  pericen-
trolobular zone was observed, with congestive
sinusoids,  centrolobular  vein  thickening,  and
necrosis.  The  abdominal  magnetic  resonance
imaging (MRI) showed a diffuse nodular infiltra-
tion of the liver (Figure 1). Because of the inef-
fectiveness of corticotherapy, methotrexate (15
mg/wk) was introduced.
In October 2005 she was referred for jaundice,
ascitis, and edema. Prothrombin time was 50%,
bilirubin  was  90  mg/L,  and  α-fetoprotein  was
normal.  A  third  liver  biopsy  was  performed,
showing  a  proliferation  of  CD31
– and  CD34
+
cells, compatible with the diagnosis of EHE or
AS. A second MRI (November, 2005) revealed a
hepatomegaly  with  diffuse,  hypervascular  and
nodular infiltration of the liver (Figure 2). The
measurement  of  the  portal  pressure  revealed
portal hypertension with a portosystemic gradi-
ent of 16 mmHg. The upper endoscopy found a
portal hypertensive gastropathy and esophageal
varices (grade 1). Clinical presentation orients
the diagnosis toward a diffuse EHE with portal
hypertension  and  hepatocellular  insufficiency.
Thus, LT was considered.
The patient underwent LT in December 2005.
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Figure  1.
Abdominal  mag-
netic  resonance
imaging  in  June
2005  (T1  without
gadolinium  injec-
tion)  showing  dif-
fuse  nodular  infil-
tration of the liver.[page 94] [Rare Tumors 2009; 1:e31]
Despite  the  preoperative  suspected  diagnosis,
AS  was  confirmed  finally  at  the  pathological
analysis of the explant, consisting of a diffuse AS
with necrosis and invasion of the centrolobular
veins (Figure 3). The initial immunosuppressive
regimen  included  prednisone  (20  mg/day),
mycophenolate  mofetyl  (1  g  x  2/day),  and
tacrolimus (6 mg x 2/day). Tacrolimus and pred-
nisone were decreased, then withdrawn in July
2006,  and  changed  to  everolimus  (3  mg/day).
Residual concentrations ranged from 10-14 µg/L.
Mycophenolate  mofetyl  was  withdrawn  in
October  2006.  A  postoperative  CT  scan  per-
formed at month 10 revealed a local recurrence
with  a  multimicronodular  infiltration  of  the
transplant  (Figure  4).  Systemic  chemotherapy
with paclitaxel was begun but had to be discon-
tinued in February 2007 owing to neurological
and mucous toxicity. Nevertheless, the CT scan
at month 16 showed a partial response, while the
patient was under everolimus and taxane thera-
py.  At  month  24,  the  patient  was  under
monotherapy with everolimus (3 g/day). She had
no  biological  toxicity  to  everolimus  and  was
managing quite well, despite a progression of
the disease with asymptomatic vertebral metas-
tasis.  At  month  30  her  general  health  status
quickly  decreased  with  terminal  liver  failure
leading to death.
Discussion
We  report  an  atypical  clinical  observation,
which is especially interesting in that it illus-
trates  the  difficulty  in  distinguishing  the  two
forms of primary sarcoma of the liver. It also
underlines the potential interest in the use of an
immunosuppressive  regimen  with  the  new
antiproliferative  agents  (mTOR  inhibitors)  in
this very particular setting. Our report is not to
promote LT for AS, based on this unusual case
study, but rather to provide some ways to opti-
mize  the  management  of  such  patients.  The
diagnosis of primary sarcoma of the liver is made
often at an advanced stage, because of its rarity
and the fact that it is asymptomatic for a long
time in patients with a normal nontumoral liver.
2
The diagnosis is confirmed by the pathological
analysis of the tumoral tissue. Although its mes-
enchymal  origin  is  assessed  easily  by  panen-
dothelial markers, the distinction between EHE
and AS remains a delicate issue, particularly on
a percutaneous liver biopsy. The main histologi-
cal criteria to assess the diagnosis of EHE are
nodes formed by a hyaline stroma, and particular
epithelioid cells with intracytoplasmic red blood
cell  inclusions,  and  sometimes  calcifications
(which are not present in AS). At the edge of the
nodes, sinusoids and hepatic veins are invaded
by tumoral cells, but the architecture of the liver
is preserved.
5 The histological characteristic of
AS is the presence of atypical tumoral cells at the
edge  of  the  sinusoids,  often  causing  vascular
dilatations  (cavernous  type),  or  more  rarely
nodular solid tumors. In both histological forms,
tumoral cells are CD31
–and CD34
+. Hepatic AS is
a rare vascular tumor (<1/10
6 persons) predomi-
nant in men (sex ratio, 4:1). The mean age is
around 60 years.
4The known risk factor for AS is
exposure to a carcinogen such as arsenic and
vinyl chloride. Metastases are found frequently
at the time of the diagnosis, mainly located in
the  lung,  spleen,  and  bones.  The  radiological
characteristics of AS are not unequivocal. MRI or
CT  scans  may  show  a  multinodular  tumor,  a
mass syndrome, or more rarely a diffuse infiltra-
tion of the liver.
6 The outcome of AS is very poor,
regardless of the kind of therapy, with an overall
mortality rate of 90% in the year of the diagno-
sis.
2 Some authors consider EHE as a low-grade
sarcoma, more frequent among women aged 30
to 40 years. It is a particular form of sarcoma in
that it has an intermediate malignant potential
and a slow rate of progression.
7 The radiological
examinations reveal a unique tumor, sometimes
difficult to distinguish from other liver cancers.
8
In AS the panendothelial markers are positive.
The gold-standard treatment is partial hepatecto-
my but, in a large number of the patients, a com-
plete resection is impossible owing to the infil-
trative pattern of the lesion.
7In this very particu-
lar situation, LT can be discussed, because post-
transplant survival is similar to that in other liver
disease.
1,3Our patient had several characteristics
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Figure  2.  Abdominal
magnetic  resonance
imaging  in  November
2005 (T1 with gadolin-
ium injection) showing
hepatomegaly  related
to hypervascular tumo-
ral  infiltration  of  the
liver. 
Figure  3.  Transversal
section  of  the  native
liver  showing  diffuse
tumoral infiltration.  
Figure 4. Injected com-
puterized  tomography
scan  (postoperative
month  10)  showing
local recurrence of liver
sarcoma.  [Rare Tumors 2009; 1:e31] [page 95]
suggestive of EHE: gender, age, absence of toxic
exposure, and a slow progression of the tumor.
Nevertheless, the fact that the tumor presented
as a hypervascular and multinodular lesion  was
less indicative of EHE, and the findings of the
liver biopsy performed before LT were compati-
ble with the diagnosis of AS. Only 16 patients
who had LT for AS and 66 for EHE were recorded
by the ELTR European Register between 1988
and 2001, representing 0.2% of the indications
for LT.1 Some isolated case reports have been
published about LT for other forms of sarcoma of
the liver (Table 2). Taking into account the high
risk of early locoregional recurrence of the dis-
ease after LT, we introduced everolimus at six
months after LT. Everolimus is an immunosup-
pressive and antiproliferative agent belonging to
the family of the mTOR inhibitors. This molecule
has a specific cytostatic effect on tumoral cell
proliferation in vivo and in vitro, and has been
evaluated  as  an  antioncogenic  therapy.
9-15
Everolimus also has an antiangiogenic action,
and is able to increase the antitumoral effect of
chemotherapy.
16 Moreover,  the  use  of  mTOR
inhibitors has been associated with a significant
decrease in the risk of developing de novo can-
cers after renal transplantation.
17 These findings
promoted an interest in using everolimus after
LT in our patient in order to delay or decrease the
recurrence of AS. A local recurrence occurred at
month 10 but, after more than two years of fol-
low-up, the outcome for our patient is better than
that previously described in the literature. This
unusual  survival  after  LT  for  AS  may  be
explained, at least in part, by the antitumoral
properties of everolimus. Finally, primary sarco-
mas of the liver are very rare tumors. EHE is an
exceptional indication for LT, although AS is a
widely recognized contraindication. The belief of
mTOR  inhibitors  having  antiproliferative  and
antiangiogenic  properties  needs  to  be  deter-
mined  in  those  cases  of  misdiagnosed  AS  in
order to delay or slow down the recurrence of the
sarcoma.
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Table 1. Comparison of the characteristics of HA and epithelioid hemangioendothe-
lioma. 
Characteristics HA Epithelioid hemangioendothelioma
Sex Male Female 
Mean age 60  40 
Risk factors Carcinogenes -
Clinical presentation Aspecific Aspecific
Radiological findings Unique Unique
Multinodular
Diffuse infiltration Calcifications
Anatomopathology No calcifications Preservation of the
Disappearance of the  architecture of the acini 
architecture of the acini
Gold-standard therapy Symptomatic Surgery (hepatectomy, 
liver transplantation)
Post-transplant outcome Poor (<5%) Good (70%)
(two-years' survival, %)
Table 2. Review of the cases of primary sarcomas of the liver reported in the literature.
Type Number of cases References
Angiosarcoma 13 ELTR register (1)
7 UNOS register (4)
Leiomyosarcoma 1 (18)
Epithelioid hemangioendothelioma  66 ELTR register (1)
7 (7)